BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32281270)

  • 1. Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
    Liu J; Li J; Chen H; Wang R; Li P; Miao Y; Liu P
    J Cell Mol Med; 2020 May; 24(10):5786-5796. PubMed ID: 32281270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
    Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
    J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scutellarin Inhibits Proliferation, Invasion, and Tumorigenicity in Human Breast Cancer Cells by Regulating HIPPO-YAP Signaling Pathway.
    Hou L; Chen L; Fang L
    Med Sci Monit; 2017 Oct; 23():5130-5138. PubMed ID: 29079722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
    Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
    Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
    Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
    Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
    Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP.
    Irie K; Nagai T; Mizuno K
    J Biol Chem; 2020 Mar; 295(10):3017-3028. PubMed ID: 31996378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.
    Ye XY; Luo QQ; Xu YH; Tang NW; Niu XM; Li ZM; Shen SP; Lu S; Chen ZW
    J Cell Mol Med; 2015 Mar; 19(3):651-63. PubMed ID: 25712415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
    Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
    Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer.
    Han Y; Tang Z; Zhao Y; Li Q; Wang E
    Mol Carcinog; 2018 Feb; 57(2):159-166. PubMed ID: 28926138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cell polarity protein Scrib functions as a tumor suppressor in liver cancer.
    Kapil S; Sharma BK; Patil M; Elattar S; Yuan J; Hou SX; Kolhe R; Satyanarayana A
    Oncotarget; 2017 Apr; 8(16):26515-26531. PubMed ID: 28460446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
    Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
    Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palmitic acid dysregulates the Hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS-STING-IRF3 signaling mechanism.
    Yuan L; Mao Y; Luo W; Wu W; Xu H; Wang XL; Shen YH
    J Biol Chem; 2017 Sep; 292(36):15002-15015. PubMed ID: 28698384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
    Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
    Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.